120 related articles for article (PubMed ID: 23842930)
1. Nephrocalcinosis induced by hyperoxaluria in rats.
Cunha NB; Kawano PR; Padovani CR; Lima Fde O; Bernardes S; Magalhães ES; Amaro CR; Amaro JL
Acta Cir Bras; 2013 Jul; 28(7):496-501. PubMed ID: 23842930
[TBL] [Abstract][Full Text] [Related]
2. Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition.
Verhulst A; Dehmel B; Lindner E; Akerman ME; D'Haese PC
Urolithiasis; 2022 Apr; 50(2):119-130. PubMed ID: 35122487
[TBL] [Abstract][Full Text] [Related]
3. Oral administration of oxalate-enriched spinach extract as an improved methodology for the induction of dietary hyperoxaluric nephrocalcinosis in experimental rats.
Albert A; Tiwari V; Paul E; Ponnusamy S; Ganesan D; Prabhakaran R; Mariaraj Sivakumar S; Govindan Sadasivam S
Toxicol Mech Methods; 2018 Mar; 28(3):195-204. PubMed ID: 28980857
[TBL] [Abstract][Full Text] [Related]
4. Nephrocalcinosis and hyperlipidemia in rats fed a cholesterol- and fat-rich diet: association with hyperoxaluria, altered kidney and bone minerals, and renal tissue phospholipid-calcium interaction.
Schmiedl A; Schwille PO; Bonucci E; Erben RG; Grayczyk A; Sharma V
Urol Res; 2000 Dec; 28(6):404-15. PubMed ID: 11221920
[TBL] [Abstract][Full Text] [Related]
5. Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants.
Sikora P; Roth B; Kribs A; Michalk DV; Hesse A; Hoppe B
Kidney Int; 2003 Jun; 63(6):2194-9. PubMed ID: 12753307
[TBL] [Abstract][Full Text] [Related]
6. Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline.
Khan SR; Glenton PA; Byer KJ
Kidney Int; 2006 Sep; 70(5):914-23. PubMed ID: 16850024
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II.
Milliner DS; Wilson DM; Smith LH
Kidney Int; 2001 Jan; 59(1):31-6. PubMed ID: 11135054
[TBL] [Abstract][Full Text] [Related]
8. Study of a rat model for calcium oxalate crystal formation without severe renal damage in selected conditions.
Yamaguchi S; Wiessner JH; Hasegawa AT; Hung LY; Mandel GS; Mandel NS
Int J Urol; 2005 Mar; 12(3):290-8. PubMed ID: 15828958
[TBL] [Abstract][Full Text] [Related]
9. Designer probiotic Lactobacillus plantarum expressing oxalate decarboxylase developed using group II intron degrades intestinal oxalate in hyperoxaluric rats.
Paul E; Albert A; Ponnusamy S; Mishra SR; Vignesh AG; Sivakumar SM; Sivasamy G; Sadasivam SG
Microbiol Res; 2018 Oct; 215():65-75. PubMed ID: 30172310
[TBL] [Abstract][Full Text] [Related]
10. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
Hoppe B; von Unruh GE; Blank G; Rietschel E; Sidhu H; Laube N; Hesse A
Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
[TBL] [Abstract][Full Text] [Related]
11. Protective impact of resveratrol in experimental rat model of hyperoxaluria.
Oksay T; Yunusoğlu S; Calapoğlu M; Aydın Candan I; Onaran İ; Ergün O; Özorak A
Int Urol Nephrol; 2017 May; 49(5):769-775. PubMed ID: 28185107
[TBL] [Abstract][Full Text] [Related]
12. Renal tubular injury induced by ischemia promotes the formation of calcium oxalate crystals in rats with hyperoxaluria.
Cao Y; Liu W; Hui L; Zhao J; Yang X; Wang Y; Niu H
Urolithiasis; 2016 Oct; 44(5):389-97. PubMed ID: 27040948
[TBL] [Abstract][Full Text] [Related]
13. Protective role of enalapril for chronic tubulointerstitial lesions of hyperoxaluria.
Toblli JE; Ferder L; Stella I; Angerosa M; Inserra F
J Urol; 2001 Jul; 166(1):275-80. PubMed ID: 11435885
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of nephrocalcinosis after renal transplantation in an adult patient with primary hyperoxaluria type I.
Knols G; Leunissen KM; Spaapen LJ; Bosman FT; vd Wiel TW; Kootstra G; van Hooff JP
Nephrol Dial Transplant; 1989; 4(2):137-9. PubMed ID: 2496356
[TBL] [Abstract][Full Text] [Related]
15. Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria.
Grujic D; Salido EC; Shenoy BC; Langman CB; McGrath ME; Patel RJ; Rashid A; Mandapati S; Jung CW; Margolin AL
Am J Nephrol; 2009; 29(2):86-93. PubMed ID: 18698135
[TBL] [Abstract][Full Text] [Related]
16. Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated hypophosphataemic rickets.
Reusz GS; Latta K; Hoyer PF; Byrd DJ; Ehrich JH; Brodehl J
Lancet; 1990 May; 335(8700):1240-3. PubMed ID: 1971321
[TBL] [Abstract][Full Text] [Related]
17. The Long Pentraxin PTX3 Is an Endogenous Inhibitor of Hyperoxaluria-Related Nephrocalcinosis and Chronic Kidney Disease.
Marschner JA; Mulay SR; Steiger S; Anguiano L; Zhao Z; Boor P; Rahimi K; Inforzato A; Garlanda C; Mantovani A; Anders HJ
Front Immunol; 2018; 9():2173. PubMed ID: 30319631
[TBL] [Abstract][Full Text] [Related]
18. Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis.
Marengo SR; Chen DH; Evan AP; Sommer AJ; Stowe NT; Ferguson DG; Resnick MI; MacLennan GT
Urol Res; 2006 Jun; 34(3):200-10. PubMed ID: 16479391
[TBL] [Abstract][Full Text] [Related]
19. Limitation of apoptotic changes in renal tubular cell injury induced by hyperoxaluria.
Sarica K; Erbagci A; Yağci F; Bakir K; Erturhan S; Uçak R
Urol Res; 2004 Aug; 32(4):271-7. PubMed ID: 15249986
[TBL] [Abstract][Full Text] [Related]
20. [Secondary hyperoxaluria and nephrocalcinosis due to ethylene glycol poisoning].
Monet C; Richard E; Missonnier S; Rebouissoux L; Llanas B; Harambat J
Arch Pediatr; 2013 Aug; 20(8):863-6. PubMed ID: 23827374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
